New research suggests a potential link between the presence of a protein associated with Parkinson’s disease and a faster rate of cognitive decline in women with Alzheimer’s disease. The findings, published in JAMA Network Open, could offer new avenues for understanding why Alzheimer’s often progresses more rapidly in women and may inform future treatment strategies.
Alzheimer’s disease is characterized by the accumulation of abnormal tau protein in the brain, disrupting communication between brain cells and leading to memory loss and cognitive impairment. Increasingly, researchers are recognizing that other protein abnormalities, specifically alpha-synuclein – a protein linked to Parkinson’s disease – are also present in some Alzheimer’s patients. This new study investigates the impact of this co-occurrence, particularly concerning gender differences.
Researchers at the Mayo Clinic found that among individuals with Alzheimer’s disease who also exhibited elevated levels of alpha-synuclein, women experienced brain changes at a rate 20 times faster than men. This suggests that alpha-synuclein may play a significant role in accelerating dementia progression in women, according to the study. “When we see changes related to the disease unfolding at vastly different speeds, we can no longer treat Alzheimer’s as if it presents identically in everyone,” explained Dr. Kejal Kantarsi, the lead author of the study, in a statement.
The research involved 415 participants diagnosed with Alzheimer’s disease. Participants underwent testing of their cerebrospinal fluid to detect abnormal alpha-synuclein and brain imaging to measure changes in tau accumulation over time. Approximately 17% of the participants showed evidence of abnormal alpha-synuclein. Identifying these sex-specific differences, Dr. Kantarsi noted, “can support us design more targeted clinical trials and, more personalized treatment strategies.”
Gender-Specific Vulnerability in Alzheimer’s
The study’s findings highlight a potential biological mechanism contributing to the disproportionate burden of Alzheimer’s disease experienced by women. Dr. Elijah Mack, a researcher involved in the study, stated that this research “opens up a completely new direction for understanding why women bear a disproportionate share of the dementia burden.” He added, “If we can unravel the mechanisms behind this vulnerability, we may uncover targets we hadn’t previously considered.”
While the exact reasons for this difference remain unclear, researchers hypothesize that hormonal factors, genetic predispositions, or differences in brain structure may contribute to the increased vulnerability of women. Further investigation is needed to fully elucidate these complex interactions. The Alzheimer’s Association reports that women account for nearly two-thirds of Americans living with Alzheimer’s disease.
Promising Results in Dravet Syndrome Treatment
In a separate development, a novel treatment for Dravet syndrome, a rare and severe form of epilepsy in children, is showing promising results. Stoke Therapeutics and Biogen have developed zurvonersen, an experimental gene-silencing therapy, that has demonstrated significant reductions in seizure frequency and improvements in quality of life for young patients.
Published in the New England Journal of Medicine, the research details how regular administration of zurvonersen for up to three years reduced seizure frequency by 91% in children with Dravet syndrome. Monthly seizure counts decreased from an average of 17 to between 1.5 and 7, depending on the dosage regimen. The study involved 81 patients aged 2 to 18, who received zorevunersen via direct injection into the cerebrospinal fluid over six months, with continued treatment for 75 of those participants every four months.
Researchers reported that zurvonersen was generally well-tolerated, with most side effects being mild to moderate. Dravet syndrome, affecting approximately 1 in 15,000 children, is notoriously challenging to treat. The condition stems from mutations in the SCN1A gene, which leads to insufficient production of a protein essential for normal nerve cell function, resulting in developmental delays, coordination and dietary issues, severe seizures, and premature death. Zurvonersen works by increasing the production of the healthy protein encoded by the SCN1A gene.
A larger-scale trial of the drug is currently underway. Dr. Helen Cross, from University College London and a lead investigator in the study, stated, “I see many patients with genetic epilepsies that are very difficult to treat, and the impact extends beyond seizures, with limited treatment options.” The mother of an 8-year-vintage boy participating in the trial shared that the treatment has “completely transformed our lives,” allowing her son to experience a quality of life previously unimaginable.
These two studies represent significant advancements in our understanding and potential treatment of neurological disorders. Further research will be crucial to validate these findings and translate them into effective therapies for patients. The ongoing investigation into the interplay between alpha-synuclein, gender, and Alzheimer’s disease progression, alongside the promising results of zurvonersen for Dravet syndrome, offer hope for improved outcomes for individuals affected by these debilitating conditions.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
What are your thoughts on these new research findings? Share your comments below, and please share this article with your network.
